We are optimistic that the insights gained from these investigations will contribute to developing future precision medicine strategies that target PBRM1 and its bromodomain interactions for cancer treatment by facilitating the correlation of specific patient missense variants with distinct alterations in PBRM1 tumor suppressor functions and activities and clinical patient outcomes. The gene discussed is PBRM1; the disease is neoplasm.